Title of cohortIntegrated multidisciplinary approach/Agrica MSA IFR Public Health 99
Name of Principal Investigator - Title
Name of Principal Investigator - First name
Name of Principal Investigator - Last name
Address of institution -InstitutionISPED / INSERM U1219 / Université de Bordeaux
Address of institution - Street address
Address of institution - City
Address of institution - Postcode
Funding sourceMSA (Gironde et caisse centrale), AGRICA
Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?Neurodegenerative disease in general
Q1b. When are studies on the above condition(s) expected to become possible?
Q2a. In a single sentence what is the stated aim of the cohort?Study of the disease, especially in association with age. Study health care use and social measures for Alzheimers disease and similar syndromes. Compare with the urban areas (3C and PAQUID)
Q2b. What distinguishes this cohort from other population cohorts?Population-based cohort. Rural population retired from agriculture
Q3a. i) Number of publications that involve use of your cohort to date
Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly availablehttp://www.ncbi.nlm.nih.gov/pubmed/?term=AMI+AND+Dartigues[Author]
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:
Q4a. Study criteria: what is the age range of participants at recruitment? To:
Q4b. Study criteria: what are the inclusion criteria?65 or more years old subjects. Retired from an agricultural activity. Resident in one of the selected towns of the countryside of Gironde. Affiliated to MSA and having, for the employees, the AGRICA complementary (70% of the sample). General practitioner in Gironde
Q4c. Study criteria: what are the exclusion criteria?Not being affiliated to MSA
Q5. What is the size of the cohort (i.e. how many participants have enrolled)?
Q6a. Please describe what measures are used to characterise participantsSociodemographic characteristics, lifestyle, medical antecedents, medications, depressive symptomatology and activity limitations were assessed at baseline and each follow-up time. A complete cognitive evaluation with systematic screening for dementia was performed at baseline and each follow-up time. Fasting blood samples were collected at baseline. Brain MRI were performed at baseline and follow-up on a subsample.
Q6b. Are there additional measures for participants with a clinical disorder?Examination by a neurologist or a geriatrician
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?
If yes please specifyPrimary endpoint: dementia; secondary endpoints: several co-morbidities, among them Parkinson, cancer, diabetes
Q7. What is the study design (select all that apply)?Longitudinal| Prospective cohort
Q8. Are your cases matched by
Q9a. Does your study include a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describeParticipants free of the disease can be used as controls
Q10a. i) Please enter the data collection start date
Q10a. ii) Please enter the data collection end dateLast follow-up: 2016; however a next follow-up is planned
Q10a. iii) Is data collection for this studyData collection ongoing| Data analysis ongoing| Closed to new patients
Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?Yes - intend to apply for funding
Other please specify hereMainly through the study + health insurance data + cancer registry
Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?Yes (participants given permission to be re-contacted via PIs)
Q13a. Please give information on the format and availability of data stored in a database (1)Data summarised in database
Q13a. Please give information on the format and availability of data stored in a database (2)
Q13a. Please give information on the format and availability of data stored in a database (3)
Q13a. Please give information on the format and availability of data stored in a database (4)
Q13b. Please give information on the format and availability of data held as individual records (1)Data is held as individual records
Q13b. Please give information on the format and availability of data held as individual records (2)
Q13b. Please give information on the format and availability of data held as individual records (3)Data held on computer based records
Q13b. Please give information on the format and availability of data held as individual records (4)
Please specify language used
Q14a. Is data available to other groups?
Q14b. If data is available to other groups what is the access policy/mechanisms for access?Apply to PI or co-ordinator at resource| Access committee mechanism
Q15. What data sharing policy is specified as a condition of use?
Q16a. Are tissues/samples/DNA available to other groups?
Q16b i) If yes, please describe below:Living donors: blood| Living donors: blood derivatives| Living donors: DNA
Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?
Types: Population Cohorts
Member States: France
Diseases: Neurodegenerative disease in general
Years: 2016
Database Categories: N/A
Database Tags: N/A
Export as PDF
